1-8 of 8
Igor Proscurshim
Close
Sort by
Journal Articles

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

Hanlon Sia, Peter T. Tan, Joshua Richter, Phoebe Joy Ho, Tara Cochrane, Hang Quach, Binod Dhakal, Igor Proscurshim, Tony Jiang, Emaryn Mancino, Yacine Salhi, Sammicheli Stefano, Girish Gudi, Andrew Garton, Eric J. Feldman, Andrew Spencer
Journal: Blood
Blood (2022) 140 (Supplement 1): 10182–10184.
https://doi.org/10.1182/blood-2022-157585
Published: 2022
Journal Articles

Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL

Sammicheli Stefano, Camille Grandclement, Valentina Labanca, Stefania De Angelis, Carole Estoppey, Myriam Chimen, Blandine Pouleau, Perrine Suere, Emilie Nallet, Ankita Srivastava, Eric J. Feldman, Igor Proscurshim, Cyril Konto, Eugene Zhukovsky, Mario Perro
Journal: Blood
Blood (2022) 140 (Supplement 1): 6237–6238.
https://doi.org/10.1182/blood-2022-162201
Published: 2022
Journal Articles

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Sanjay R Mohan, Cristiana Costa Chase, Jesus G Berdeja, Lionel Karlin, Karim Belhadj, Aurore Perrot, Philippe Moreau, Cyrille Touzeau, Thomas Chalopin, Alexander M Lesokhin, Carol Ann Huff, David H. Vesole, Joshua Richter, Jeffrey V. Matous, Igor Proscurshim, Eileen Wolff, Girish Gudi, Andrew Garton, Vinu Menon, Sunitha Gn, Yacine Salhi, Eric J. Feldman, Mohamad Mohty
Journal: Blood
Blood (2022) 140 (Supplement 1): 7264–7266.
https://doi.org/10.1182/blood-2022-157525
Published: 2022
Journal Articles

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models

Maria Patra-Kneuer, Akito Nakamura, Keli Song, Stephen Grossman, Andrea Polzer, Carmen Ginzel, Stefan Steidl, Allison J Berger, Igor Proscurshim, Christina Heitmüller
Journal: Blood
Blood (2021) 138 (Supplement 1): 2268.
https://doi.org/10.1182/blood-2021-150718
Published: 2021
Journal Articles

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, Alejandro Gomez-Pinillos, Alonzo Martinez, Bo Chao, Allison J Berger, John Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda W. Cooper, Paolo F Caimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2488.
https://doi.org/10.1182/blood-2021-152225
Published: 2021
Journal Articles

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Sagar Lonial, Stefano R. Tarantolo, Ralph V. Boccia, Habte Yimer, Moshe Y. Levy, Rafat Abonour, Meera Mohan, Vivek Roy, Jeremy T. Larsen, Saulius K. Girnius, Cara A. Rosenbaum, Omar Nadeem, Deborah Berg, Bo Chao, Allison J Berger, Akito Nakamura, Yuhong Zhang, Keli Song, Christine K. Ward, Igor Proscurshim, Shaji Kumar
Journal: Blood
Blood (2021) 138 (Supplement 1): 2742.
https://doi.org/10.1182/blood-2021-148385
Published: 2021
Journal Articles

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Gilles Salles, MD PhD, Daniel J. Landsburg, MD, Giuseppe Gritti, MD PhD, Krish Patel, MD, Herve Tilly, MD PhD, Catherine Thieblemont, MD PhD, William Townsend, MRCP,MDFRCPath, Silvia Ferrari, MD, Kate F. Stumpo, BA, Shilpi Katyayan, Cheryl Li, Harry Miao, MD, Igor Proscurshim, Ajay K. Gopal, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5310.
https://doi.org/10.1182/blood-2019-125650
Published: 2019
Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim
Journal: Blood
Blood (2019) 134 (Supplement_1): 1593.
https://doi.org/10.1182/blood-2019-128773
Published: 2019